Mubarak A Alamri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7505713/publications.pdf

Version: 2024-02-01

32 papers	1,239 citations	840776 11 h-index	501196 28 g-index
35 all docs	35 docs citations	35 times ranked	2293 citing authors

#	Article	IF	Citations
1	Synthesis, characterization, biological evaluation and molecular docking of a new quinazolinone-based derivative as a potent dual inhibitor for VEGFR-2 and EGFR tyrosine kinases. Journal of Biomolecular Structure and Dynamics, 2022, 40, 6810-6816.	3.5	12
2	Analyzing the effect of mutations in SARS-CoV2 papain-like protease from Saudi isolates on protein structure and drug-protein binding: Molecular modelling and dynamics studies. Saudi Journal of Biological Sciences, 2022, 29, 526-533.	3.8	3
3	Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study. Molecules, 2022, 27, 1159.	3.8	8
4	Anti-Diabetic Activity of Bioactive Compound Extracted from Spondias mangifera Fruit: In-Vitro and Molecular Docking Approaches. Plants, 2022, 11, 562.	3.5	14
5	Thymoquinone Induced Leishmanicidal Effect via Programmed Cell Death in Leishmania donovani. ACS Omega, 2022, 7, 10718-10728.	3.5	4
6	Anti-Obesity Action of Boerhavia diffusa in Rats against High-Fat Diet-Induced Obesity by Blocking the Cannabinoid Receptors. Plants, 2022, 11, 1158.	3.5	3
7	Structural Elucidation of Rift Valley Fever Virus L Protein towards the Discovery of Its Potential Inhibitors. Pharmaceuticals, 2022, 15, 659.	3.8	13
8	Discovery of Rift Valley fever virus natural pan-inhibitors by targeting its multiple key proteins through computational approaches. Scientific Reports, 2022, 12, .	3.3	13
9	Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL^{pro}. Journal of Biomolecular Structure and Dynamics, 2021, 39, 4936-4948.	3.5	103
10	Fabrication of Sensitive Membrane Electrodes and their Application in Electrochemical Quantification of Ibandronate in Dosage Form. Electroanalysis, 2021, 33, 249-255.	2.9	0
11	Inhibition of Chikungunya Virus Infection by 4-Hydroxy-1-Methyl-3-(3-morpholinopropanoyl)quinoline-2(1H)-one (QVIR) Targeting nsP2 and E2 Proteins. ACS Omega, 2021, 6, 9791-9803.	3.5	9
12	Solid-phase extraction and validated spectrofluorimetric quantification of pamidronate in human plasma. Tropical Journal of Pharmaceutical Research, 2021, 19, 2651-2657.	0.3	1
13	Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies. Molecules, 2021, 26, 2992.	3.8	9
14	Discovery of anti-MERS-CoV small covalent inhibitors through pharmacophore modeling, covalent docking and molecular dynamics simulation. Journal of Molecular Liquids, 2021, 330, 115699.	4.9	35
15	Adamantane-derived scaffolds targeting the sigma-2 receptor; an in vitro and in silico study. Saudi Pharmaceutical Journal, 2021, 29, 1166-1172.	2.7	2
16	Structural insight into the binding pattern and interaction mechanism of chemotherapeutic agents with Sorcin by docking and molecular dynamic simulation. Colloids and Surfaces B: Biointerfaces, 2021, 208, 112098.	5.0	27
17	Evaluation of Haloxylon Persicum Leaves Ethanolic Extract for Phytochemical, Antioxidant, Anticancer, and Antimicrobial Properties. Current Topics in Nutraceutical Research, 2021, 20, 424-430.	0.1	0
18	Discovery of human coronaviruses pan-papain-like protease inhibitors using computational approaches. Journal of Pharmaceutical Analysis, 2020, 10, 546-559.	5.3	67

#	Article	IF	Citations
19	Structure-based virtual screening and molecular dynamics of phytochemicals derived from Saudi medicinal plants to identify potential COVID-19 therapeutics. Arabian Journal of Chemistry, 2020, 13, 7224-7234.	4.9	43
20	Computational screening of natural and natural-like compounds to identify novel ligands for sigma-2 receptor. SAR and QSAR in Environmental Research, 2020, 31, 837-856.	2.2	5
21	Pharmacoinformatics and molecular dynamic simulation studies to identify potential small-molecule inhibitors of WNK-SPAK/OSR1 signaling that mimic the RFQV motifs of WNK kinases. Arabian Journal of Chemistry, 2020, 13, 5107-5117.	4.9	18
22	Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. Journal of Pharmaceutical Analysis, 2020, 10, 313-319.	5.3	721
23	Spectrophotometric and spectrodensitometric quantification of a new antiviral combination. Journal of Planar Chromatography - Modern TLC, 2020, 33, 79-87.	1.2	4
24	Structure prediction of SPAK C-terminal domain and analysis of its binding to RFXV/I motifs by homology modelling, docking, and molecular dynamics simulation studies. Current Computer-Aided Drug Design, 2020, 16, 666-675.	1.2	0
25	Sequence specific assignment and determination of OSR1 C-terminal domain structure by NMR. Biochemical and Biophysical Research Communications, 2019, 512, 338-343.	2.1	5
26	Pharmacophore and docking-based sequential virtual screening for the identification of novel Sigma 1 receptor ligands. Bioinformation, 2019, 15, 586-595.	0.5	17
27	C-terminal phosphorylation of SPAK and OSR1 kinases promotes their binding and activation by the scaffolding protein MO25. Biochemical and Biophysical Research Communications, 2018, 503, 1868-1873.	2.1	8
28	The Photosensitising Clinical Agent Verteporfin Is an Inhibitor of SPAK and OSR1 Kinases. ChemBioChem, 2018, 19, 2072-2080.	2.6	24
29	Rafoxanide and Closantel Inhibit SPAK and OSR1 Kinases by Binding to a Highly Conserved Allosteric Site on Their Câ€terminal Domains. ChemMedChem, 2017, 12, 639-645.	3.2	40
30	Towards the Development of Smallâ€Molecule MO25 Binders as Potential Indirect SPAK/OSR1 Kinase Inhibitors. ChemBioChem, 2017, 18, 460-465.	2.6	9
31	WNK Signaling Inhibitors as Potential Antihypertensive Drugs. ChemMedChem, 2017, 12, 1677-1686.	3.2	8
32	Computational Exploration of Potential Polo-Like Kinase 1 Inhibitors as New Chemotherapeutic Agents. Journal of Pharmaceutical Research International, 0, , 18-30.	1.0	1